Metformin - Life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 5, 2007, Pages 247-252

  Campbell, Ian W ^a,b  

^a VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; MONOTHERAPY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OPTIMAL DRUG DOSE; OVARY POLYCYSTIC DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

EID: 35848943883     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070051001     Document Type: Conference Paper

References (29)

1. Bailey C J, Day C. Metformin: its botanical background. Practical Diabetes Int 2004;21:115-17.
2. Hadden DR. Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edin 2005;35:258-60.
3. Joslin EP. Proceedings of the nineteenth annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, USA, May 2, 1927. J Clin Invest 1927;4:435-6.
4. Sterne J. Du Nouveau dans les antidiabétiques, La NN diméthylamino guanyl guanidine (N.N.D.G.). Maroc Med 1957; 36:1295-6.
5. Rambert P, Canivet J, Quichaud F, Spitz B. Treatment of diabetes mellitus with NN-dimethil-diguanide. La Medecin en France. 1961;September:29-37.
6. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-6.
7. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
8. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit-Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
9. Kao J, Tobis J, McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-50.
10. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29:6S36-6S43.
11. Sgambato S, Varricchio M, Tesauro P, Passariello N, Carbone L. L'utilisation de la metformin dans la cardiopathie ischemique. Clin Ter 1980;94:77-85.
12. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37:1344-50.
13. Katakami N, Yamasaki Y, Hayaishi-Okano R et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes. Diabetologia 2004;47:1906-13.
14. Garber AJ, Duncan TG, Goodman AM et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.
15. Fujioka K, Brazg RL, Raz I et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005;7:28-39.
16. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD002966.
17. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
18. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
19. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
20. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or mefformin. N Engl J Med 2002;346:393-403.
21. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289-97.
22. Wenying Y, Lixiang L, Jinwu Q, et al. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab 2001;17:131-4.
23. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9.
24. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med 2007; 24:451-63.
25. National Institute for Health and Clinical Excellence. Guideline CG11 Fertility. Available at http://www.nice.org.uk/guidance/CG11/guidance/ pdf/English (accessed March 2007).
26. American Association of Clinical Endocrinologists. Position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Available at http://www.aace.com/pub/pdf/guidelines/ PCOSpositionstatement.pdf (accessed October 2007)
27. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-05.
28. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.
29. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006; 29:1963-72.